/PRNewswire/ The U.S. Food and Drug Administration (FDA) granted Emergency Use Authorization (EUA) for investigational bamlanivimab (LY-CoV555) 700 mg and.
FDA Authorizes Lilly COVID-19 Antibody Combination for Emergency Use
February 10, 2021
The FDA has granted Emergency Use Authorization (EUA) for a 700 mg dose of bamlanivimab (LY-CoV555) in combination with a 1400 mg dose of a second Lilly antibody candidate, etesevimab (LY-CoV016), for the treatment of mild to moderate COVID-19 in patients aged 12 and older who are at high risk for progressing to severe COVID-19 and/or hospitalization. [Eli Lilly]
Share
The FDA last night granted Emergency Use Authorization (EUA) for a 700 mg dose of bamlanivimab (LY-CoV555) in combination with a 1400 mg dose of a second Lilly antibody candidate, etesevimab (LY-CoV016), for the treatment of mild to moderate COVID-19 in patients aged 12 and older who are at high risk for progressing to severe COVID-19 and/or hospitalization.
The Food and Drug Administration (FDA) has issued emergency approval to an antibody drug combo treatment from Eli Lilly for high-risk patients recently diagnosed with coronavirus disease.
The U.S. Food and Drug Administration has granted an Emergency Use Authorization for two COVID-19 antibody therapies from Indianapolis-based Eli Lilly and Co. (NYSE: LLY). The company says the combina
The USFDA has approved EUA for investigational bamlanivimab and etesevimab as a combination therapy for the treatment of mild to moderate Covid-19 patients.